Literature DB >> 19959692

Utility and relationships of biomarkers of smoking in African-American light smokers.

Man Ki Ho1, Babalola Faseru, Won S Choi, Nicole L Nollen, Matthew S Mayo, Janet L Thomas, Kolawole S Okuyemi, Jasjit S Ahluwalia, Neal L Benowitz, Rachel F Tyndale.   

Abstract

Although expired carbon monoxide (CO) and plasma cotinine (COT) have been validated as biomarkers of self-reported cigarettes per day (CPD) in heavy smoking Caucasians, their utility in light smokers is unknown. Further, variability in CYP2A6, the enzyme that mediates formation of COT from nicotine and its metabolism to trans-3'-hydroxycotinine (3HC), may limit the usefulness of COT. We assessed whether CO and COT are correlated with CPD in African-American light smokers (< or =10 CPD, n = 700), a population with known reduced CYP2A6 activity and slow COT metabolism. We also examined whether gender, age, body mass index, smoking mentholated cigarettes, or rate of CYP2A6 activity, by genotype and phenotype measures (3HC/COT), influence these relationships. At baseline, many participants (42%) exhaled CO of < or =10 ppm, the traditional cutoff for smoking, whereas few (3.1%) had COT below the cutoff of < or =14 ng/mL; thus, COT seems to be a better biomarker of smoking status in this population. CPD was weakly correlated with CO and COT (r = 0.32-0.39, P < 0.001), and those reporting fewer CPD had higher CO/cigarette and COT/cigarette, although the correlations coefficients between these variables were also weak (r = -0.33 and -0.08, P < 0.05). The correlation between CPD and CO was not greatly increased when analyzed by CYP2A6 activity, smoking mentholated cigarettes, or age, although it appeared stronger in females (r = 0.38 versus 0.21, P < 0.05) and obese individuals (r = 0.38 versus 0.24, P < 0.05). Together, these results suggest that CO and COT are weakly associated with self-reported cigarette consumption in African-American light smokers, and that these relationships are not substantially improved when variables previously reported to influence these biomarkers are considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959692      PMCID: PMC2791893          DOI: 10.1158/1055-9965.EPI-09-0956

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  45 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Individual differences in nicotine intake per cigarette.

Authors:  Freda Patterson; Neal Benowitz; Peter Shields; Vyga Kaufmann; Christopher Jepson; Paul Wileyto; Susan Kucharski; Caryn Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

3.  Light smokers: issues and recommendations.

Authors:  Kolawole S Okuyemi; Kari Jo Harris; Monica Scheibmeir; Won S Choi; Joshua Powell; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2002       Impact factor: 4.244

4.  Ethnic differences in N-glucuronidation of nicotine and cotinine.

Authors:  N L Benowitz; E J Perez-Stable; I Fong; G Modin; B Herrera; P Jacob
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

5.  Pharmacokinetics of nicotine in healthy elderly people.

Authors:  L Molander; A Hansson; E Lunell
Journal:  Clin Pharmacol Ther       Date:  2001-01       Impact factor: 6.875

6.  Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies.

Authors:  Edward F Domino; Lisong Ni
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-10       Impact factor: 5.067

7.  R.J. Reynolds' targeting of African Americans: 1988-2000.

Authors:  Edith D Balbach; Rebecca J Gasior; Elizabeth M Barbeau
Journal:  Am J Public Health       Date:  2003-05       Impact factor: 9.308

8.  Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.

Authors:  M K Ho; J C Mwenifumbo; N Al Koudsi; K S Okuyemi; J S Ahluwalia; N L Benowitz; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2009-03-11       Impact factor: 6.875

9.  Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.

Authors:  Jasjit S Ahluwalia; Kari Jo Harris; Delwyn Catley; Kolawole S Okuyemi; Matthew S Mayo
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

10.  Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women.

Authors:  Karen L Ahijevych; Rachel F Tyndale; Ravinder K Dhatt; Harrison G Weed; Kristine K Browning
Journal:  Nicotine Tob Res       Date:  2002-11       Impact factor: 4.244

View more
  21 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Authors:  Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia
Journal:  J Natl Cancer Inst       Date:  2012-01-25       Impact factor: 13.506

3.  A pilot clinical trial of varenicline for smoking cessation in black smokers.

Authors:  Nicole L Nollen; Lisa Sanderson Cox; Niaman Nazir; Edward F Ellerbeck; Ashli Owen; Sydni Pankey; Nia Thompson; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2011-04-15       Impact factor: 4.244

4.  CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations.

Authors:  Catherine A Wassenaar; Yuanqing Ye; Qiuyin Cai; Melinda C Aldrich; Joanne Knight; Margaret R Spitz; Xifeng Wu; William J Blot; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2014-11-21       Impact factor: 4.944

Review 5.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

6.  Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation.

Authors:  Andy Z X Zhu; Matthew J Binnington; Caroline C Renner; Anne P Lanier; Dorothy K Hatsukami; Irina Stepanov; Clifford H Watson; Connie S Sosnoff; Neal L Benowitz; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2012-10-01       Impact factor: 4.944

7.  Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.

Authors:  A Joseph Bloom; Timothy B Baker; Li-Shiun Chen; Naomi Breslau; Dorothy Hatsukami; Laura J Bierut; Alison Goate
Journal:  Hum Mol Genet       Date:  2013-09-17       Impact factor: 6.150

8.  Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.

Authors:  Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox
Journal:  Addict Behav       Date:  2012-11-29       Impact factor: 3.913

9.  Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Authors:  Taku Nagano; Makiko Shimizu; Kazuma Kiyotani; Tetsuya Kamataki; Ryohji Takano; Norie Murayama; Fumiaki Shono; Hiroshi Yamazaki
Journal:  Int J Environ Res Public Health       Date:  2010-07-20       Impact factor: 3.390

10.  The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.

Authors:  Andy Z X Zhu; Caroline C Renner; Dorothy K Hatsukami; Gary E Swan; Caryn Lerman; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-31       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.